| Literature DB >> 26657898 |
Martin Köhler1, Michael Röring1, Björn Schorch2, Katharina Heilmann3, Natalie Stickel4, Gina J Fiala5, Lisa C Schmitt6, Sandra Braun7, Sophia Ehrenfeld8, Franziska M Uhl8, Thorsten Kaltenbacher8, Florian Weinberg6, Sebastian Herzog9, Robert Zeiser10, Wolfgang W Schamel11, Hassan Jumaa12, Tilman Brummer13.
Abstract
Despite being mutated in cancer and RASopathies, the role of the activation segment (AS) has not been addressed for B-Raf signaling in vivo. Here, we generated a conditional knock-in mouse allowing the expression of the B-Raf(AVKA) mutant in which the AS phosphoacceptor sites T599 and S602 are replaced by alanine residues. Surprisingly, despite producing a kinase-impaired protein, the Braf(AVKA) allele does not phenocopy the lethality of Braf-knockout or paradoxically acting knock-in alleles. However, Braf(AVKA) mice display abnormalities in the hematopoietic system, a distinct facial morphology, reduced ERK pathway activity in the brain, and an abnormal gait. This phenotype suggests that maximum B-Raf activity is required for the proper development, function, and maintenance of certain cell populations. By establishing conditional murine embryonic fibroblast cultures, we further show that MEK/ERK phosphorylation and the immediate early gene response toward growth factors are impaired in the presence of B-Raf(AVKA). Importantly, alanine substitution of T599/S602 impairs the transformation potential of oncogenic non-V600E B-Raf mutants and a fusion protein, suggesting that blocking their phosphorylation could represent an alternative strategy to ATP-competitive inhibitors.Entities:
Keywords: BRAF fusion; Cre/loxP system; MAPK pathway; Ras; gene targeting
Mesh:
Substances:
Year: 2015 PMID: 26657898 PMCID: PMC4718462 DOI: 10.15252/embj.201592097
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598